Page 1

PRESS RELEASE immatics . . • • Immatics Announces Second Quarter 2026 Financial Results and Business Update Enrollment in the SUPRAME Phase 3 trial of anzu - cel ( anzutresgene autoleucel , IMA203 ) remains on track to complete the required randomizations by year - end to support final analysis for the primary PFS endpoint ; aggregate PFS events ( progression or death ) occurring more slowly than originally modeled Company plans to proceed directly to a streamlined final analysis for the primary endpoint , PFS , while strengthening power for the secondary endpoint , OS , to enhance the commercial product profile SUPRAME topline data disclosure for the final PFS analysis expected in H1 2027 , followed by BLA submission in 2027 Anzu - cel PRAME Cell Therapy : Updated Phase 1b data at ASCO 2026 continued to show durable anti - tumor activity in metastatic melanoma , with 56 % CORR , 14.6 months mDOR , 6.1 months mPFS , 16.2 months mOS and a 2 - year OS rate of 46 % , as well as predictable and manageable tolerability • IMA203CD8 PRAME Cell Therapy : Updated Phase 1 data presented at ASCO 2026 demonstrated clinical activity in hard - to - treat gynecologic cancers with a 63 % ORR and 50 % CORR ; updated data across multiple PRAME - positive solid tumors are planned for presentation at the ESMO Congress 2026 • IMA402 PRAME Bispecific : Phase 1b data at recommended Phase 2 dose ( RP2D ) range across multiple cancers planned for presentation at the ESMO Congress 2026 . IMA402 PRAME / IMA401 MAGEA4 / 8 Bispecific Combination : Combination cohort in sqNSCLC enrolling patients with first data expected in 2027 Immatics Press Release August 18 , 2026 1 | 13